Overview

Treatment of a Single Patient With CRD-TMH-001

Status:
Enrolling by invitation

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

The study is a single patient study intended to understand the effects of a gene-editing therapeutic to treat a rare mutation of Duchenne muscular dystrophy.

Phase:

Phase 1

Details

Lead Sponsor:

Cure Rare Disease, Inc

Collaborator:

University of Massachusetts, Worcester